This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Teriparatide Nasal Spray
Marina Biotech, Inc.
Drug Names(s): Intranasal Parathyroid Hormone, PTH1-34 Nasal Spray
Description: PTH1-34 is a fragment of the naturally occurring human parathyroid hormone that is an important regulator of calcium and phosphorus metabolism. Nastech's intranasal PTH1-34 uses Nastech's proprietary Tight Junction technology to enhance delivery of this therapeutic peptide to provide an alternative to injections.
Deal Structure: In February 2006, Nastech and Procter & Gamble announced a collaboration to develop and commercialize PTH1-34 nasal spray for the treatment of osteoporosis. Under the terms of the agreement, Nastech grants P&G rights to the worldwide development and commercialization of PTH1-34 nasal spray, in exchange for an upfront fee, milestone payments, and double-digit royalties on product sales.
P&G assumes responsibility for clinical and non-clinical studies and regulatory approval. Nastech is responsible for the chemistry, manufacturing and controls (CMC) sections of regulatory submissions. P&G directs worldwide sales, marketing, and promotion of PTH1-34 nasal spray. If a supply agreement is reached between the companies, Nastech will be responsible for all manufacturing of the intranasal PTH1-34 and will supply clinical and commercial product to P&G.
In June 2006, Nastech announced an agreement with Procter & Gamble to manufacture and supply PTH1-34 nasal spray. This agreement further...See full deal structure in Biomedtracker
Teriparatide Nasal Spray News
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Additional information available to subscribers only: